Project: blood PRotein Identification to Discriminate dEmentias

Acronym	bPRIDE (Reference Number: JPND2019-466-162)
Project Topic	The increasing global prevalence of the most common forms of neurodegenerative dementias (Alzheimer’s disease (AD), Frontotemporal dementia (FTD) and Dementia with Lewy bodies (DLB)) poses an enormous pressure on the social and economic systems worldwide, calling for the development of efficient disease-modifying therapies. Failure of current treatment paradigms is partly explained by the lack of sensitive tests for early and specific diagnosis of the different types of dementia using accessible body fluids. Specific diagnosis of dementia types is essential for optimal stratification of patients to target the specific pathologies. Additionally, early diagnosis allows implementation of specific prevention strategies and/or treatments before extensive neuronal damage has taken place. Unfortunately, early and specific diagnostic tests in peripheral blood for neurodegenerative dementias are still not available and thus there is an urgent need to identify easily accessible biomarkers able to effectively discriminate between AD, FTD and DLB at the earliest possible stage. bPRIDE will address this ambitious challenge by mapping the plasma proteome of an unprecedented well-characterized large multinational dementia cohort using novel, robust and translatable proteomics technologies. We aim to develop plasma biomarker panel(s) that enable early and specific diagnosis of the main dementia types and translate them into commutable diagnostic tests. Linking these biomarkers to specific biological mechanisms will pave the way for implementation of differential diagnostic tests for early-disease dementia, which will strongly contribute to the development of precision medicine. The strong public and patient involvement of bPRIDE includes efficient engagement of different stakeholders, enabling us to take into account their needs and concerns throughout the project.
Network	JPCOFUND2
Call	PERSONALISED MEDICINE FOR NEURODEGENERATIVE DISEASES

Project partner

Number	Name	Role	Country
1	Vrije Universiteit Medical Center	Coordinator	Netherlands
2	Charles University	Partner	Czech Republic
3	Hospital de la Santa Creu i Sant Pau	Partner	Spain
4	The University of Melbourne	Partner	Australia
5	Lund University	Partner	Sweden
6	Ulm Universtity	Partner	Germany
7	University of Perugia	Partner	Italy